New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London has provided the ...

Researchers have long believed — and the authors of a new study hypothesized — that schizophrenics have lower brain levels of the neurotransmitter serotonin, and that those lower levels are associated ...

Reviva Pharmaceuticals said the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine after a ...

Reviva Pharmaceuticals Holdings Inc. may be headed back to the clinic for another phase III study of brilaroxazine in treating schizophrenia. With a successful series of early and mid-stage studies ...

Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the ...

Reviva Pharmaceuticals Inc. (NASDAQ: RVPH), a late clinical stage pharmaceutical company aiming to revolutionize the schizophrenia treatment market with Brilaroxazine, its developmental drug, made ...

First it was wine. Then it was weed. Now? Mushrooms. Microdosing psilocybin, the active compound in so-called “magic ...

Zai Lab Limited today announced that China's National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for COBENFY® (xanomeline and trospium chloride) for the treatment ...

IS YOUR sex life more flat than fire? The reason could be closer than you think. In fact, it could be sitting in your ...

Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the ...

In the UK, new schemes to support mental health are introducing to people an unexpected skill: stand-up comedy.

Investing.com -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) stock plummeted 46% in premarket trading Tuesday after the company disclosed that the FDA has recommended conducting a second Phase ...